Efficacy and Safety of Budesonide Orodispersible Tablets for Eosinophilic Esophagitis up to 3 Years: An Open-Label Extension Study
Clinical and histologic remission of EoE could be maintained with BOT in a large majority of patients for up to 96 weeks, and for up to 144 weeks in patients with uninterrupted BOT therapy across all trials. No additional safety concerns were identified with long-term BOT treatment (ClinicalTrials.gov, Number: NCT02493335).
Authors
- Alex Straumann (ORCID: https://orcid.org/0000-0002-1428-6404)
- Cecílio Santander (ORCID: https://orcid.org/0000-0001-5492-2535)
- Ahmed Madisch (ORCID: https://orcid.org/0000-0001-9163-5893)
- Alain Schoepfer (ORCID: https://orcid.org/0000-0001-6341-9536)
- Michael Vieth (ORCID: https://orcid.org/0000-0002-4336-7721)
- Stephan Miehlke (ORCID: https://orcid.org/0000-0002-9174-8270)
- Petr Hrúz (ORCID: https://orcid.org/0000-0003-2767-0445)
- Stefan Schubert (ORCID: https://orcid.org/0000-0002-8878-7375)
- Ulrike von Arnim (ORCID: https://orcid.org/0000-0003-3214-0166)
- Albert Jan Bredenoord (ORCID: https://orcid.org/0000-0001-5918-2062)
- Luc Biedermann (ORCID: https://orcid.org/0000-0003-0824-4125)
- Christoph Schmöcker
- Christoph Schlag (ORCID: https://orcid.org/0000-0003-3227-2724)
- Alfredo José Lucendo (ORCID: https://orcid.org/0000-0003-1183-1072)
- Constanza Ciriza de los Ríos (ORCID: https://orcid.org/0000-0002-1217-1881)
- Jamal Hayat (ORCID: https://orcid.org/0000-0002-5461-2550)
- Stephen Attwood
- Michael B. Halstead
- Ralph Müeller
- Sabrina Pfurr
Institutions
- Bethany College - West Virginia (US)
- Universität Hamburg (DE)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Durham University (GB)
- St George’s University Hospitals NHS Foundation Trust (GB)
- Bayreuth Medical Center (DE)
- Centre Hospitalier Universitaire Vaudois (CH)
- University Hospital of Basel (CH)
- Sana Klinikum Lichtenberg (DE)
- Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (ES)
- University Hospital of Zurich (CH)
- University Medical Center Hamburg-Eppendorf (DE)
- Hospital General de Tomelloso (ES)
- St George's Hospital (GB)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
- Agaplesion Bethanien Krankenhaus (DE)
- Pathodiagnostik Berlin (DE)
- University Hospital Magdeburg (DE)
- Amsterdam University Medical Centers (NL)
- Dr Falk Pharma (Germany) (DE)
- Pharmaxis (Australia) (AU)
- University of Lausanne (CH)
Publication Details
- Journal
- Clinical Gastroenterology and Hepatology
- Published
- 2024-12-16
- DOI
- https://doi.org/10.1016/j.cgh.2024.10.034
- Citations
- 12
- Primary Topic
- Eosinophilic Esophagitis
- Type
- article
- Field-Weighted Citation Impact
- 6.87
Funders
- Dr. Falk Pharma